EUCTR2010-020744-35-PT进行中（未招募）不适用
A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Response to DMARDs - OSKIRA - 2
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Male or female aged 18 and over
- •2. A diagnosis of RA after the age of 16
- •3. Currently taking 1 of the following traditional DMARDs: methotrexate, sulfasalazine, hydroxychloroquine or chloroquine.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Females who are pregnant/lactating
- •2.Any systemic inflammatory conditions(other than RA), connective tissue disease or chronic pain disorders that may interfere with the interpretation of the outcome data
- •3. Poorly controlled blood pressure
- •4.History of liver function abnormality requiring investigation, drug induced liver injury, chronic liver disease, excessive alcohol consumption/chronic alcohol induced disease
研究者
相似试验
进行中（未招募）
不适用
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not Responding. (OSKIRA - 1)MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2010-020743-12-PLAstraZeneca AB900
进行中（未招募）
不适用
A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Response to DMARDs. D4300C00002 - OSKIRA-2Patients with active Rheumatoid Arthritis despite current treatment with a DMARD.MedDRA version: 9.1Level: PTClassification code 10039073EUCTR2010-020744-35-ITASTRAZENECA900
进行中（未招募）
不适用
A Phase III, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Fostamatinib Disodium in Rheumatoid Arthritis Patients with an Inadequate Response to DMARDsEstudio en fase III, multicéntrico, aleatorizado, dobleciego, controlado con placebo y de grupos paralelos para evaluar dos pautas posológicas defostamatinib disódico en pacientes con artritis reumatoide que tienen una respuesta insuficientea los FARME - OSKIRA - 2Rheumatoid ArthritisArtritis reumatoideMedDRA version: 12.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2010-020744-35-ESAstraZeneca AB900
进行中（未招募）
不适用
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding. (OSKIRA - 2)MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-020744-35-LTAstraZeneca AB900
进行中（未招募）
不适用
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding. (OSKIRA - 2)MedDRA version: 13.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2010-020744-35-GBAstraZeneca AB900